Artificial Intelligence

Advantest's T2000 AiR2X isn't just new hardware. It's a calculated move to solve the chip industry's legacy pains and efficiency demands.

A landmark UK study reveals an AI diagnostic tool that predicts heart attacks with stunning accuracy and offers a £25 million lifeline to strained health budgets.

How Circus SE's autonomous robot is set to revolutionize corporate dining, tackling food waste and augmenting the workforce at a top auto plant.

A new rapid saliva test from ImpetusDX promises to revolutionize oral care by linking gum health to systemic disease, but can it overcome market hurdles?

OMRON's new global ECG strategy leverages AI and key acquisitions to tackle heart disease, aiming to eliminate adverse cardiovascular events.

With a massive $550M capital infusion, Immunovant is poised to accelerate its novel Graves' Disease therapy, IMVT-1402, toward commercial launch.

The industrial giant secured a rare dual 'A' rating from CDP. We decode what this means for its strategy, competitors, and ESG-focused investors.

Major e-commerce sales are fueling a tech race. How brands like EZVIZ use deep discounts to make advanced home security a reality for millions.

A new partnership aims to bypass slow, costly banking rails, using stablecoins to unlock faster, cheaper global transactions for businesses. Is this the future?

SSC's 37th dividend payment signals stability, but high payout ratios raise questions. Is management's growth-and-buyback strategy the right bet?

Natera's Signatera test salvaged key insights from a failed clinical trial, creating a new roadmap for personalized breast cancer treatment and logistics.

Ancient remedies meet modern AI. See how companies are using data and smart factories to transform traditional Chinese medicine into a global pharma force.

A new partnership uses AI to analyze imaging, clinical, and molecular data, offering unprecedented accuracy in predicting breast cancer recurrence years later.

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.

An energy services giant just sold its nuclear arm to a startup in a stock deal. It's a strategic pivot to mass-produce reactors for the AI power crunch.

Match Group bets big on the future of dating, spinning out an AI venture while a new CEO steers Hinge toward its projected $1 billion revenue goal.

A new pact on quantum computing and AI safety aims to do more than innovate—it seeks to build a secure, equitable digital world for every citizen.

A $3 billion drop in assets at AllianceBernstein, driven by client withdrawals in a flat market, signals a deeper challenge for active asset managers.

Nordson's record earnings reveal the high-tech backbone of premium goods and a resilient, behind-the-scenes investment in the high life.

Early trial data suggests GRI-0621 could be a game-changer for Idiopathic Pulmonary Fibrosis, showing lung repair and a much better safety profile.